ALPINE IMMUNE SCIENCES
Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
ALPINE IMMUNE SCIENCES
Industry:
Biotechnology Health Care Medical
Founded:
2015-01-23
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.alpineimmunesciences.com
Total Employee:
101+
Status:
Active
Contact:
(206)441-5062
Total Funding:
475.3 M USD
Technology used in webpage:
Content Delivery Network IPv6 ReCAPTCHA ReCAPTCHA V2 CloudFront Gravity Forms ASP.NET Ajax Google Analytics IP Anonymization CenturyLink Q4Web
Similar Organizations
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Dermavant Sciences
Dermavant Sciences is a biotechnology company focused on dermatology.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Ocean Biomedical
Ocean Biomedical is a biotechnology company that accelerates new discoveries in the world of medicine.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-07-20 | Nivalis Therapeutics | Nivalis Therapeutics acquired by Alpine Immune Sciences | N/A |
Investors List
TCG Crossover
TCG Crossover investment in Post-IPO Equity - Alpine Immune Sciences
Omega Funds
Omega Funds investment in Post-IPO Equity - Alpine Immune Sciences
Decheng Capital
Decheng Capital investment in Post-IPO Equity - Alpine Immune Sciences
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Equity - Alpine Immune Sciences
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Alpine Immune Sciences
OrbiMed
OrbiMed investment in Post-IPO Equity - Alpine Immune Sciences
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Alpine Immune Sciences
Logos Capital
Logos Capital investment in Post-IPO Equity - Alpine Immune Sciences
Avidity Partners
Avidity Partners investment in Post-IPO Equity - Alpine Immune Sciences
Omega Funds
Omega Funds investment in Post-IPO Equity - Alpine Immune Sciences
Key Employee Changes
Official Site Inspections
http://www.alpineimmunesciences.com Semrush global rank: 2.94 M Semrush visits lastest month: 5.39 K
- Host name: crs.ultradns.net
- IP address: 204.74.99.100
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alpine Immune Sciences"
Alpine Immune Sciences - Crunchbase Company …
Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders.See details»
Vertex Pharmaceuticals | Home
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.See details»
Press Release - Vertex Pharmaceuticals Newsroom
Apr 10, 2024 - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, …See details»
Alpine Immune Sciences, Inc. | LinkedIn
Alpine Immune Sciences is now part of Vertex Pharmaceuticals. Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with ...See details»
Alpine Immune Sciences, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Alpine Immune Sciences, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Vertex Pharmaceuticals to Acquire Alpine Immune …
The deal would give the pharmaceutical giant access to Alpine’s potential treatment for chronic kidney disease.See details»
Alpine Immune Sciences - Overview, News & Similar companies
May 9, 2024 Who is Alpine Immune Sciences. Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, …See details»
Alpine Immune Sciences - PitchBook
May 7, 2021 Alpine Immune Sciences General Information Description. Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat …See details»
Alpine Immune Sciences Provides Corporate Update and Reports …
Mar 17, 2022 Alex Sharif Director, Investor Relations and Corporate Development Alpine Immune Sciences, Inc. 206-788-4545 [email protected] Kelli Perkins (Media) …See details»
Alpine Immune Sciences - Craft
Alpine Immune Sciences has 3 employees across 2 locations, $49.3 m in total funding, and $58.88 m in annual revenue in FY 2023. See insights on Alpine Immune Sciences including …See details»
Alpine Immune Sciences Announces Company Presentation and …
Apr 5, 2022 Investor Relations Alex Sharif Director, Investor Relations and Corporate Development Alpine Immune Sciences, Inc 206-788-4545 [email protected] …See details»
Alpine Immune Sciences to Highlight Clinical Updates on …
Sep 12, 2022 SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments …See details»
Alpine Immune - Alpine Immune Sciences Reports Second Quarter …
Aug 11, 2020 SEATTLE -(BUSINESS WIRE)-Aug. 11, 2020- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing …See details»
Alpine Immune Sciences to Participate in Two Upcoming …
SEATTLE, February 01, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for …See details»
Alpine Immune Sciences Announces $91 Million Private Placement
Sep 15, 2021 Investor Relations Alex Sharif Director, Investor Relations and Corporate Development Alpine Immune Sciences, Inc 206-788-4545 [email protected] …See details»
Alpine Immune Sciences Provides Corporate Update and Full Year …
Mar 18, 2024 Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, …See details»
Alpine Immune Sciences and AbbVie Announce Option and …
Jun 18, 2020 - Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building …See details»
Alpine Immune Sciences Reports Second Quarter 2023 Financial …
Aug 14, 2023 -The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023- Alpine …See details»
Alpine Immune Sciences and Horizon Therapeutics plc Announce …
Dec 16, 2021 Investors: Alex Sharif Director, Investor Relations and Corporate Development 206.788.4545 [email protected]. Media: Kelli Perkins 310.625.3248 …See details»